SIRPant Immunotherapeutics develops an approach to elicit tumor-specific T-cells through one of two alternative means: in vivo or ex vivo.
SIRPant Immunotherapeutics has raised $6.2M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in August 2021.
SIRPant Immunotherapeutics is headquartered in Hummelstown, United States.
SIRPant Immunotherapeutics develops an approach to elicit tumor-specific T-cells through one of two alternative means: in vivo or ex vivo.
SIRPant Immunotherapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SIRPant Immunotherapeutics — Funding & Investors." VCBacked, August 5, 2021, https://www.vcbacked.co/company/sirpant-immunotherapeutics. Accessed August 13, 2026.
VCBacked. (2021). SIRPant Immunotherapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/sirpant-immunotherapeutics
{{cite web |title=SIRPant Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sirpant-immunotherapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated